Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.QLT has reported that a phase II clinical trial of lemuteporfin- injectable in patients with benign prostatic hyperplasia (BPH) did not meet the study's primary efficacy objective at three months.
Subscribe to our email newsletter
While the decrease in AUA (American Urological Association) symptom score was consistent with that seen after other minimally invasive therapies there was no significant difference between treatment and sham-control groups, the company said.
“The preliminary result of this trial does not support initiation of phase III clinical trials of lemuteporfin in BPH at this time,” commented Bob Butchofsky, QLT’s acting CEO. “We intend to complete the analysis of the data, including the six-month measurements, in order to determine the best path forward.”
QLT is a biopharmaceutical company specializing in developing treatments for eye diseases as well as dermatological and urological conditions. The company’s products include Visudyne and Eligard.